@prefix biolink: . @prefix ns1: . @prefix this: . @prefix sub: . @prefix schema: . @prefix np: . @prefix dct: . @prefix rdf: . @prefix xsd: . @prefix rdfs: . @prefix orcid: . @prefix prov: . @prefix npx: . sub:Head { this: np:hasAssertion sub:assertion; np:hasProvenance sub:provenance; np:hasPublicationInfo sub:pubinfo; a np:Nanopublication . } sub:assertion { biolink:category biolink:Disease . sub:association rdf:object ; rdf:predicate biolink:treats; rdf:subject ; a rdf:Statement; rdfs:label "\"ZELNORM is contraindicated in patients with: A history of myocardial infarction (MI), stroke, transient ischemic attack (TIA), or angina [see Warnings and Precautions (5.1) A history of ischemic colitis or other forms of intestinal ischemia [see Warnings and Precautions (5.2) Severe renal impairment (eGFR< 15 mL/min/1.73 m 2 [see Use in Specific Populations (8.6) Moderate and severe hepatic impairment (Child-Pugh B or C) [see Use in Specific Populations (8.7) A history of bowel obstruction, symptomatic gallbladder disease, suspected sphincter of Oddi dysfunction, or abdominal adhesions [see Adverse Reactions (6.2) Hypersensitivity to tegaserod [see Adverse Reactions (6.2) ZELNORM is contraindicated in patients with: A history of myocardial infarction, stroke, transient ischemic attack, or angina. ( 4 5.1 A history of ischemic colitis or other forms of intestinal ischemia. ( 4 5.2 Severe renal impairment (eGFR< 15 mL/min/1.73 m 2 4 8.6 Moderate or severe hepatic impairment (Child-Pugh B or C). ( 4 8.7 A history of bowel obstruction, symptomatic gallbladder disease, suspected sphincter of Oddi dysfunction, or abdominal adhesions. ( 4 Hypersensitivity to tegaserod. ( 4\""; biolink:provided_by ; biolink:relation schema:MedicalContraindication . biolink:category biolink:Drug . } sub:provenance { sub:assertion prov:wasAttributedTo orcid:0000-0002-1468-3557 . } sub:pubinfo { sub:sig npx:hasAlgorithm "RSA"; npx:hasPublicKey "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB"; npx:hasSignature "HMpAN/ZLAiirJ0dlGD2UuaPZ7LKEBwrf2JA4ZsjRPcg2IJ0rov5ynpWH9odQraW2JKDIExFrpyJqG7XB53q9ysnb6ceOxqO1r1BhZH20ivER7b12CBzWRThwvtaYTJxibEkRo5mG6J7G2XX+oPaTclLx92lBGH8NkaFT7RTPUhI="; npx:hasSignatureTarget this: . this: dct:created "2021-08-23T19:01:06.583+02:00"^^xsd:dateTime; dct:creator orcid:0000-0002-1468-3557; ns1:wasCreatedFromProvenanceTemplate ; ns1:wasCreatedFromPubinfoTemplate ; ns1:wasCreatedFromTemplate . }